Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40 milligram(s) - proton pump inhibitors; pantoprazole

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 2.5 milligram(s) - ace inhibitors, plain; ramipril

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 10 milligram(s) - ace inhibitors, plain; ramipril

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 1.25 milligram(s) - ace inhibitors, plain; ramipril

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - ramipril - tablet - 5 milligram(s) - ace inhibitors, plain; ramipril

Malta - Kiingereza - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents

Malta - Kiingereza - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents

Malta - Kiingereza - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - memantine hydrochloride - film-coated tablet - memantine hydrochloride 10 mg - psychoanaleptics

Malta - Kiingereza - Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - memantine hydrochloride - film-coated tablet - memantine hydrochloride 20 mg - psychoanaleptics

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.copdsymptomatic treatment of patients with severe copd (fev1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.